Mundra Vaibhav, Li Wei, Mahato Ram I
Department of Pharmaceutical Sciences, University of Nebraska Medical Center (UNMC), 986025 Nebraska Medical Center, Omaha, NE 68198-6025, USA.
Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA.
Nanomedicine (Lond). 2015;10(16):2613-33. doi: 10.2217/nnm.15.111. Epub 2015 Aug 5.
Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.
起源于黑素细胞的黑色素瘤是最具侵袭性的皮肤癌类型,治疗选择有限。随着BRAF和MEK抑制剂的发现,新的靶向治疗方案已显示出显著的生存益处。尽管最近取得了进展,但化疗耐药性和全身毒性的发展仍然是治疗转移性黑色素瘤的一个挑战。虽然使用达卡巴嗪进行黑色素瘤一线治疗的缓解率仅为5%-10%,但长期使用针对致癌基因BRAF突变的靶向治疗会产生化疗耐药性。在这篇综述中,我们将讨论基于纳米颗粒的策略,即将药物封装并与聚合物结合,以通过增强的渗透和滞留效应最大化其在肿瘤中的分布。我们还将重点介绍光动力疗法和黑色素瘤靶向纳米颗粒的设计。